MedPath

Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:1
Completed:0

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)

Phase II Study to Evaluate Efficacy and Safety of AMP Peptide PL-5 in Mild Infections of Diabetic Foot Ulcers

Phase 2
Active, not recruiting
Conditions
Diabetic Foot Ulcers
Interventions
Drug: Antimicrobial Peptide PL-5 Topical Spray and Placebo
First Posted Date
2024-01-03
Last Posted Date
2025-05-25
Lead Sponsor
Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.
Target Recruit Count
90
Registration Number
NCT06189638
Locations
🇺🇸

ILD Research Center, Vista, California, United States

🇺🇸

Bioresearch Partner Holdings, LLLP, Miami, Florida, United States

🇺🇸

Santos Research Center, Corp, Tampa, Florida, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath